Revised US Biosecure Act Could Unlock Opportunities For Indian Pharma Companies

The revised US Biosecure Act is returning for discussion in Congress, reviving debates around biotechnology security and the role of foreign firms in America’s health ecosystem.

The US Senate blocked the bill on Dec. 9, 2024, following which the stock of CDMO companies reacted negatively. Since then, Divi’s Laboratories has gained 1.05%, while Laurus Labs has surged 56.49%. In contrast, Syngene International has declined 23.37%, Neuland Laboratories is down 0.53%, and Jubilant Pharmova has fallen 4.04%.